US WorldMeds (USWM) reported the successful closing of the previously announced acquisition of Adaptimmune Therapeutics plc’s (Adaptimmune) cell–therapy assets—including TECELRA ® (afamitresgene ...

Axon Enterprise posts strong Q2 2025 results, showcasing 33% revenue growth, record bookings, and robust AI adoption.

Gain insights into Ichor Holdings' Q2 2025 earnings, CEO transition, hiring impacts on margins, key milestones, and cautious Q3 outlook.

Positive results from a mid-stage study apparently weren’t enough to raise investor confidence in Praxis Precision Medicines ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

The retailer declined to provide guidance in the face of a shifting tariff environment, but notched sales growth in North ...

Fintel reports that on August 4, 2025, TD Cowen upgraded their outlook for Affiliated Managers Group (NYSE:AMG) from Hold to ...

Fintel reports that on August 4, 2025, TD Cowen initiated coverage of Akero Therapeutics (NasdaqGS:AKRO) with a Buy ...

Tech stocks soared last month, but the biggest winners on the S&P 500 were from a different part of the market.

Berkshire Hathaway reported a 4% drop in Q2 operating profit and a $3.8 billion Kraft Heinz writedown amid falling insurance ...

Axon Enterprise, Inc. (NASDAQ: AXON) ranks among the best growth stocks to buy for the next 10 years. Ahead of the company’s ...

Just because a stock is a Dividend Champion doesn't mean it's an overall winner. However, some members of the group could be attractive to investors. Here are three Dividend Champion stocks I'm ...